Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group

Cancer

Volumn 118, Issue 18, 2012, Pages 4597-4605

  Janeway, Katherine A ^a   Barkauskas, Donald A ^b   Krailo, Mark D ^b   Meyers, Paul A ^c   Schwartz, Cindy L ^d   Ebb, David H ^e   Seibel, Nita L ^f   Grier, Holcombe E ^a   Gorlick, Richard ^g   Marina, Neyssa ^h  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^h LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

adolescent; osteosarcoma; outcome; prognosis; young adult

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MIFAMURTIDE; RAZOXANE; TOPOTECAN; TRASTUZUMAB;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ETHNICITY; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NORTH AMERICA; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS TUMOR; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEX;

ADOLESCENT; ADULT; AGE FACTORS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862837194     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27414     Document Type: Article

References (24)

1. Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. NIH Pub. No. 06-6067. Bethesda, MD: National Institutes of Health; 2006. Available at: http://planning.cancer.gov/library/AYAO-PRG-Report-2006-FINAL.pdf.
2. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B,. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008; 8: 288-298.
3. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694-701.
4. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998; 16: 3628-3633.
5. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A,. Comparing adult and pediatric rhabdomyosarcoma in the Surveillance, Epidemiology and End Results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009; 27: 3391-3397.
6. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A,. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009; 115: 3537-3547.
7. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001; 12: 1145-1150.
8. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009; 45: 2367-2375.
9. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P,. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106: 1154-1161.
10. Harting MT, Lally KP, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol. 2010; 136: 561-570.
11. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790.
12. Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943. Cancer. 2007; 109: 1646-1653.
13. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011.
14. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 633-638.
15. Bishop S, Feinberg SE, Holland YMM,. Discrete Multivariate Analysis. Cambridge, MA: MIT Press; 1975.
16. Gooley TA, Leisenring W, Crowley J, Storer BE,. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706.
17. Gray R,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
18. Kalbfleisch JD, Prentice RL,. The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley and Sons; 2002.
19. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006.
20. Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol. 2005; 27: 129-134.
21. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992; 10: 5-15.
22. Kaste SC, Liu T, Billups CA, Daw NC, Pratt CB, Meyer WH,. Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer. 2004; 43: 723-728.
23. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996; 14: 848-858.
24. Ferrari A, Miceli R, Meazza C, et al. Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size. J Clin Oncol. 2009; 27: 371-376.